Clinical and Translational Allergy最新文献

{"title":"Correction to “Higher Prevalence of Dupilumab-Induced Ocular Adverse Events in Atopic Dermatitis Compared to Asthma: A Daily Practice Analysis”","authors":"","doi":"10.1002/clt2.70154","DOIUrl":"10.1002/clt2.70154","url":null,"abstract":"<p>A. R. Schlösser, L. Bult, J. C. Thelen, et al., “Higher Prevalence of Dupilumab-Induced Ocular Adverse Events in Atopic Dermatitis Compared to Asthma: A Daily Practice Analysis,” <i>Clinical and Translational Allergy</i> (2024): e12386, https://doi.org/10.1002/clt2.12386.</p><p>In the results of the Abstract section, the text ‘Additionally, 20% of AD and <b>17.6%</b> of SA patients discontinued dupilumab treatment…’ was incorrect. The correct value for SA patients should be <b>8.6%</b> instead of 17.6%. This is accurately reflected later in the main text. Fortunately, this typo does not affect any conclusions or other major aspects of the article, and the overall findings remain unchanged.</p><p>We apologize for this error.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 2","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70154","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146206367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult-Onset Compared to Childhood-Onset Asthma: Multifaceted Symptoms, Comorbidity, and Healthcare Burden","authors":"Reshed Abohalaka,&nbsp;Selin Ercan,&nbsp;Lauri Lehtimäki,&nbsp;Daniil Lisik,&nbsp;Saliha Selin Ozuygur Ermis,&nbsp;Helena Backman,&nbsp;Madeleine Rådinger,&nbsp;Bright I. Nwaru,&nbsp;Hannu Kankaanranta","doi":"10.1002/clt2.70160","DOIUrl":"10.1002/clt2.70160","url":null,"abstract":"<p>In this study, we compared symptoms, comorbidities, and healthcare burden between childhood-onset asthma (&lt; 18 years) and early adult-onset (18–39 years) and late adult-onset asthma (≥ 40 years). Among 3546 participants with data on physician-diagnosed asthma and onset age, 46.4% were defined as adult-onset [864 (24.4%) had early adult-onset asthma (18–39 years) and 782 (22.1%) had late adult-onset asthma (≥ 40 years)], which, compared to childhood-onset asthma, presented with more complex, multi-symptom profiles, including productive cough, sputum production, but less wheezing. Allergy-related comorbidities were more common in childhood-diagnosed asthma, while chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, obesity, and chronic sinusitis were more common in adult-onset asthma. Adult-onset asthma also had a higher disease burden, with more frequent medication use and exacerbations. Adult-onset asthma has an underlying complexity, contributing to a vicious cycle of worsening symptoms, increased medication use, and more comorbidities.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 2","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12906355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146197367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-Life Safety of Japanese Cedar Pollen Sublingual Immunotherapy Tablets: A Post-Marketing Survey","authors":"Minoru Gotoh,&nbsp;Yuriko Maekawa,&nbsp;Tsuyoshi Ando,&nbsp;Noboru Kato,&nbsp;Eiji Horikawa,&nbsp;Noriaki Nishino","doi":"10.1002/clt2.70157","DOIUrl":"10.1002/clt2.70157","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Japanese cedar (JC) pollen sublingual immunotherapy (SLIT)-tablets (5000 Japanese allergy units [JAU]) are licensed for the treatment of JC-pollinosis with no age restriction on the basis of the results of a 5-year clinical trial. However, there have been no large-scale surveys of 5000 JAU in an actual clinical setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a multicenter observational prospective study. We assessed the safety and effectiveness of the long-term use of 5000 JAU in patients with JC-pollinosis, with an observation period of two seasons of JC pollen dispersal, at clinical sites in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our safety analysis included 516 patients and the effectiveness analysis included 469 patients. Adverse drug reactions (ADRs) occurred in 68 patients (13.18%) and mainly comprised administration site-related events that occurred during the early phase of administration. Treatment discontinuation due to ADRs occurred in 18 patients (3.49%). No deaths, anaphylactic shock, or serious ADRs occurred. Regarding effectiveness, the severity of JC-pollinosis was rated as “almost asymptomatic + mild” in 82.19% of patients in Season 1 and 92.58% in Season 2. Quality of life was rated as “score 0 (Fine) + 1” in 75.83% of patients in Season 1 and 86.09% in Season 2. Overall improvement was rated as “improved + slightly improved” in 95.68% of patients in Season 1 and 96.38% in Season 2 following the initiation of JC pollen SLIT-tablets. Nasal and ocular symptom scores also decreased with increasing treatment duration. Treatment continuation rates were 89.53% in Season 1 and 78.29% in Season 2.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The JC pollen SLIT-tablets appear to be safe and effective in an actual clinical setting during two seasons. No new safety or effectiveness issues were identified, and no additional safety or effectiveness precautions were required.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 2","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12904777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146194169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Importance of Smell Loss to Patients With Chronic Rhinosinusitis With Nasal Polyps: Options for Management and Recovery","authors":"Thomas S. Higgins,&nbsp;Jennifer E. Douglas,&nbsp;Robert C. Kern,&nbsp;James N. Palmer,&nbsp;Sietze Reitsma,&nbsp;Martin Wagenmann,&nbsp;Rhea Goodman,&nbsp;Mark Corbett,&nbsp;Cristina Almansa,&nbsp;Amr Radwan","doi":"10.1002/clt2.70149","DOIUrl":"10.1002/clt2.70149","url":null,"abstract":"<p>Primary diffuse type 2-dominant chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease of the nasal cavity and paranasal sinuses associated with significant morbidity. Impaired sense of smell is a cardinal symptom of CRSwNP and one of the most burdensome for patients, impacting quality of life, mental health, and even safety. Mechanisms of smell loss in CRSwNP may be related to conductive losses due to significant burden of nasal polyps, as well as the impact of type 2 inflammatory mediators on olfactory sensory neurons. Initial medical management frequently involves intranasal or oral corticosteroids. Patients whose symptoms remain uncontrolled by medical treatment may be offered sinonasal surgery; however, patients may experience recurrence of smell loss following surgery. Guidelines recommend biologics for certain patients with CRSwNP after undergoing complete endoscopic sinus surgery, and data from clinical trials and real-world evidence support their effectiveness in improving sense of smell. Given the impact of smell loss, shared decision-making is important in identifying treatment options best suited to achieving patient goals. This review provides an overview of the importance of smell loss in CRSwNP and its known mechanisms, and reviews the evidence for the efficacy of current treatment options in restoring sense of smell.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 2","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12860424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146092267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR)","authors":"Isam Alobid,&nbsp;Sven F. Seys,&nbsp;Joost de Kinderen,&nbsp;Valérie Hox,&nbsp;Carlo Cavaliere,&nbsp;Alexandros Andrianakis,&nbsp;Sven Schneider,&nbsp;Martin Wagenmann,&nbsp;Martin Bruch,&nbsp;Adriana Izquierdo-Domínguez,&nbsp;Xavier Gonzalez-Compta,&nbsp;Laura Pardo Muñoz,&nbsp;Laura Van Gerven,&nbsp;Peter W. Hellings,&nbsp;Geoffrey Mortuaire,&nbsp;Martin Burian,&nbsp;Mireia Golet-Fors,&nbsp;Mathilde Moyaert,&nbsp;Peter-Valentin Tomazic,&nbsp;Giulia Bettio,&nbsp;Marco de Vincentiis,&nbsp;Zuzana Diamant,&nbsp;Julia Eckl-Dorna,&nbsp;Gert Mariën,&nbsp;Simonetta Masieri,&nbsp;Christina Morgenstern,&nbsp;Kathrin Scheckenbach,&nbsp;Aldine Tu,&nbsp;Camilo Rodriguez van Strahlen,&nbsp;Claus Bachert,&nbsp;CHRINOSOR consortium","doi":"10.1002/clt2.70153","DOIUrl":"10.1002/clt2.70153","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The SYNAPSE phase 3 study demonstrated that mepolizumab significantly improves nasal polyp score (NPS), quality of life and symptom severity in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>We aimed to evaluate mepolizumab effectiveness in a real-world cohort from 12 tertiary centers in 6 European countries.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methodology</h3>\u0000 \u0000 <p>A retrospective analysis was conducted in 110 CRSwNP patients (comorbid asthma: 86.4%). CRS-related outcomes were analyzed at baseline, 24 and 52 weeks of mepolizumab. Treatment response was evaluated based on EUFOREA 2021 criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Significant improvements in NPS, Sinonasal Outcome Test-22 (SNOT-22), and visual analog scale (VAS) symptom scores were observed at 24 and 52 weeks compared to baseline. Further improvement between weeks 24 and 52 was observed for NPS and SNOT-22. Asthma Control Test (ACT) also improved significantly by week 24 (ACT score ≥ 20: 64.5%). At least one response criterion (change in SNOT-22 ≥ 8.9, NPS ≥ 1, VAS total sinus symptoms ≥ 20, VAS nasal blockage ≥ 20, VAS loss of smell ≥ 20) was met by 85.6% and 78.7% of patients at 24 and 52 weeks, respectively. A more stringent composite response (SNOT-22 &lt; 30, NPS &lt; 4, VAS total sinus symptoms &lt; 50, and VAS nasal blockage &lt; 50) was achieved in 18.3% and 44.6% of patients at 24 and 52 weeks, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Mepolizumab demonstrated clinically meaningful benefits in a real-world CRSwNP population, with nearly half of patients achieving a beneficial composite treatment response by week 52. Notably, progressive improvements between weeks 24 and 52 underscore the value of prolonged therapy and the importance of evaluating treatment response at one year.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 2","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12860572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146096653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between the Angioedema Control Test and Attack Frequency in Hereditary Angioedema","authors":"Aaron Yarlas,&nbsp;Alexandra J. Feld,&nbsp;Jakob B. Bjorner,&nbsp;Cary Thurm,&nbsp;Laura Bordone,&nbsp;Kenneth B. Newman,&nbsp;Sabrina Treadwell,&nbsp;Danny M. Cohn","doi":"10.1002/clt2.70143","DOIUrl":"10.1002/clt2.70143","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hereditary angioedema (HAE), defined by unpredictable, painful, acute swelling attacks affecting several bodily locations, diminishes patients' quality of life. Assessing disease activity, burden, and treatment response pose challenges in routine care. The patient-reported Angioedema Control Test (AECT) is a subjective measure of HAE disease control. Criterion validity of AECT with objective measures of disease control has not been previously assessed. This study evaluates the criterion validity of AECT using investigator-confirmed HAE attack rate in patients with HAE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Phase 3 OASIS-HAE study (NCT05139810) randomized patients with HAE to receive donidalorsen 80 mg or placebo subcutaneously for 24 weeks. The full analysis population included all dosed patients (<i>N</i> = 90), pooled across treatment arms. This post-hoc analysis examined the correlation between AECT and HAE attacks at Baseline, 12, and 24 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>AECT scores correlated moderately to strongly with HAE attack rate (<i>ρ</i> = −0.40 to −0.85). Mean attack rates differed significantly between poor (AECT &lt; 10) and well-controlled (AECT ≥ 10) disease subgroups at study visits. At Week 24, 97.4% of patients reporting complete disease control (AECT maximum score of 16) had an attack rate of 0; the remaining patient had 1 attack. Patients with no attacks had a mean AECT score of 15.1 versus 7.7 for patients with attack rates &gt; 0.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study supports the criterion validity of AECT in patients with HAE scores. AECT scores were strongly associated with objective disease control. AECT may be a valuable tool for monitoring disease control in patients with HAE.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 1","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12795239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tezepelumab Improves Small Airways Dysfunction in Severe Asthma: A 52-Week Real-World Study","authors":"Francesco Menzella,&nbsp;Marcello Cottini,&nbsp;Elena Parazzini,&nbsp;Rory Chan,&nbsp;Laura Ventura,&nbsp;Michele Mondoni,&nbsp;Annamaria Bosi,&nbsp;Michela Bortoli,&nbsp;Gianenrico Senna,&nbsp;Carlo Lombardi,&nbsp;Lorenzo Corsi,&nbsp;Silvia Tonin,&nbsp;Andrea Rastelli,&nbsp;Cristina Albrici,&nbsp;Giulia Carone,&nbsp;Maria Sartor,&nbsp;Tatiana Scandiuzzi Piovesan,&nbsp;Maria Rita Marchi","doi":"10.1002/clt2.70147","DOIUrl":"10.1002/clt2.70147","url":null,"abstract":"&lt;p&gt;To the Editor&lt;/p&gt;&lt;p&gt;Small airway dysfunction (SAD) is a critical trait in severe asthma (SA), driving exacerbation risk and oral corticosteroid (OCS) dependence, yet it often remains undetected by conventional spirometry [&lt;span&gt;1&lt;/span&gt;]. Advanced techniques, such as oscillometry, now allow for its non-invasive assessment in clinical practice. Tezepelumab, a monoclonal antibody that blocks the upstream alarmin TSLP, has demonstrated broad efficacy across SA phenotypes by targeting alarmins high up in the inflammatory cascade [&lt;span&gt;2&lt;/span&gt;]. However, its long-term, real-world impact on SAD remains insufficiently defined except for preliminary remarks [&lt;span&gt;3&lt;/span&gt;]. We aimed to evaluate the 52-week effectiveness of tezepelumab in a cohort of 27 SA patients stratified by SAD and Type 2 (T2) inflammatory status.&lt;/p&gt;&lt;p&gt;This prospective, multicentre, real-world study included 27 consecutive adult subjects with SA. At baseline, patients were stratified according to the presence of SAD, defined as inspiratory or expiratory reactance values below the lower limit of normal, and by T2 status, with T2-high defined as blood eosinophil count (BEC) &gt; 150 cells/μL and/or fractional exhaled nitric oxide (FeNO) &gt; 20 ppb. All outcomes were assessed at baseline, 6 and 12 months. Adherence to 4-weekly subcutaneous administration and follow-up visits was strictly monitored through hospital pharmacy dispensation records and scheduled clinical visits at baseline, 6, and 12 months.&lt;/p&gt;&lt;p&gt;Statistical analysis were conducted using non-parametric tests owing to the small sample size (&lt;i&gt;N&lt;/i&gt; = 27) and non-normal dat distribution, as assessed by the Shapiro–Wilk test. Differences between independent groups (SAD vs. non-SAD) were evaluated using the Mann–Whitney &lt;i&gt;U&lt;/i&gt; test. Associations between categorical variables were analyzed using chi-squared or Fisher's exact tests. Longitudinal changes across time points (baseline vs. 6 vs. 12 months) were assessed using the Friedman test. Categorical variables were compared using Fisher's exact test. A two-sided &lt;i&gt;p&lt;/i&gt; value &lt; 0.05 was considered statistically significant. At baseline, 48% of the cohort exhibited SAD. These patients displayed significantly lower forced expiratory volume in 1 s (FEV&lt;sub&gt;1&lt;/sub&gt;) and forced vital capacity (FVC; Supporting Information S1: Table S1), higher total airway resistance (Rrs5), and more abnormal reactance at 5 Hz (Xrs5) and reactance area (AX) compared to the non-SAD group (Supporting Information S1: Table S2; Table 1).&lt;/p&gt;&lt;p&gt;Treatment with tezepelumab led to an improvement of ACT score by 6 points at 12 months, while the Asthma Quality of Life Questionnaire (AQLQ) score increased by 1.0 unit, both exceeding the minimal clinically important difference by a factor of two (Table 2, Figure S1). Tezepelumab induced a marked reduction in annualized exacerbation rates and maintenance OCS (mOCS) use across all phenotypes (&lt;i&gt;p&lt;/i&gt; &lt; 0.001). By 12 months, mOCS was discontinued","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 1","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12782232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Haptoglobin as a Predictor of Treatment Response in Patients With Chronic Spontaneous Urticaria","authors":"Kun-Woo Park,&nbsp;Boyoun Choi,&nbsp;Da-Hye Moon,&nbsp;Se-Min Park,&nbsp;Young-Min Ye","doi":"10.1002/clt2.70148","DOIUrl":"10.1002/clt2.70148","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic spontaneous urticaria (CSU) is a mast cell-driven disease associated with systemic inflammation and altered immune responses. Haptoglobin (HP), an acute-phase glycoprotein, exhibits antioxidative and immunomodulatory properties, while zonulin, the precursor of HP-2, regulates epithelial barrier integrity. We investigated the clinical relevance of serum HP and zonulin in CSU and their association with treatment outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Serum HP and zonulin levels were measured by ELISA in 124 CSU patients and 57 healthy controls (HCs). In 62 CSU patients, follow-up samples were obtained after 3 months of treatment. Clinical outcomes included the urticaria activity score over 7 days (UAS7) and the urticaria control test (UCT).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Serum HP levels were significantly higher in CSU patients than in HCs (median 1145.1 vs. 839.2 μg/mL, <i>p</i> &lt; 0.001), whereas zonulin levels did not differ. HP correlated positively, but weakly, with the white blood cell count, C3 and C-reactive protein (all rho ≈ 0.2), and negatively with disease duration and eosinophil percentage. Zonulin correlated negatively with UCT scores but not with HP. After treatment, HP decreased significantly (<i>p</i> &lt; 0.001), with greater reductions in patients showing a ≥ 12-point improvement on the UAS7. Baseline HP was higher in patients who achieved complete control (UCT = 16) than others (<i>p</i> = 0.017). ROC analysis identified baseline HP ≥ 1249 μg/mL as an optimal cutoff, confirmed as an independent predictor of complete control (odds ratio = 4.23, <i>p</i> = 0.029).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Serum HP is elevated in CSU patients, decreases with treatment, and independently predicts complete urticaria control. HP may serve as a potentially prognostic biomarker for CSU.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 1","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12777545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T Cell/Mast Cell Crosstalk in the Skin of Patients Suffering From Immune-Mediated Diseases, Focusing on Chronic Spontaneous Urticaria","authors":"Elias Toubi,&nbsp;Raeda Mubariki,&nbsp;Zahava Vadasz","doi":"10.1002/clt2.70145","DOIUrl":"10.1002/clt2.70145","url":null,"abstract":"<p>The crosstalk between immune cells in skin lesions of numerous immune-mediated diseases such as atopic dermatitis, psoriasis and other T cell mediated is fundamental for understanding the pathogenesis and treating these diseases. The mechanisms by which most activated immune cells such as T cells, mast cells, and neutrophils are shifted from peripheral blood into inflamed skin, and by which they interact, are complex and different in all these diseases. However, once immune cells are infiltrated into the skin, they are polarized to be in close proximity to each other, leading to their further activation and the production of pro-inflammatory cytokines. The immune synapse in patients' skin suffering from chronic spontaneous urticaria (CSU) is fundamental for mast cell activation and degranulation. The role of T cell-mast cell proximity in the pathogenesis of CSU is fairly assessed. A better understanding of this scenario is important for developing beneficial therapies when standard treatment fails to achieve remission.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 1","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12748527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145854709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations Between the Maternal Diet Index and Childhood Asthma: The NorthPop and Healthy Start Cohorts","authors":"Stina Bodén,&nbsp;Carina Venter,&nbsp;Kaci Pickett-Nairne,&nbsp;Deborah H. Glueck,&nbsp;Richard Lundberg-Ulfsdotter,&nbsp;Magnus Domellöf,&nbsp;Dana Dabelea,&nbsp;Christina E. West","doi":"10.1002/clt2.70144","DOIUrl":"10.1002/clt2.70144","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>A novel maternal diet index (MDI), characterizing offspring asthma- and allergy-associated maternal intake during pregnancy was constructed and validated in Healthy Start, USA. This study aims to (1) externally validate the asthma findings from Healthy Start in the NorthPop Birth Cohort Study (NorthPop) in Sweden; and (2) characterize the diet and demographics of the two cohorts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The MDI was computed as a weighted combination of seven components associated with offspring allergies and asthma, including vegetables and yogurt (associated with decreased odds) and cold cereals, fried potatoes, juice, red meat, and rice (associated with increased odds). Doctor diagnoses provided childhood asthma incidence and timing. Parametric Weibull time-to-event analysis evaluated associations between the MDI, dichotomized at the median (72.2) for Healthy Start, and offspring asthma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The NorthPop and Healthy Start mean MDI values differed significantly (<i>p</i> &lt; 0.001) and in NorthPop, only 6.1% had MDI &lt; 72.2. Data from 6446 mother-child dyads in NorthPop yielded a crude hazard ratio (HR) for asthma of 0.70 (95% confidence interval [CI] 0.50–0.98, <i>p</i> = 0.037) and a fully adjusted HR of 0.84 (0.55–1.29; <i>p</i> = 0.428) for MDI &gt; 72.2 versus &lt; 72.2 (<i>n</i> = 4655). The fully adjusted HR for 945 Healthy Start dyads was significant at HR 0.41 (0.29–0.57; <i>p</i> &lt; 0.0001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Results show that in a population with different maternal dietary patterns and demographics compared to the source population, MDI &gt; 72.2 was not an independent predictor of offspring asthma. Further proof of the utility and generalizability of the MDI needs to be tested in other populations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 12","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12713374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145773686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}